Precipio Inc (PRPO)

This article compares two specialty cancer diagnostics companies, Precipio, Inc. (PRPO) and Biodesix, Inc. (BDSX), to determine which stock is a better investment. While both operate in cancer diagnostics, they have different business focuses and financial profiles. The analysis concludes that PRPO is the better buy due to its attractive valuation, expanding product commercialization, integrated pathology-product model, and improving financial sustainability.

Precipio (PRPO) shares gained significantly following strong Q2 2026 earnings, with net sales up 24.7% year-over-year to $7 million. Despite a net loss, the company saw substantial growth in service and product revenues, improved gross profit and adjusted EBITDA, and generated positive operating cash flow. Management highlighted record quarterly revenue and an expanding customer base, expecting continued growth.

Precipio Diagnostics reported record Q2 2025 revenue of $7.0 million, a 22.8% increase year-over-year, marking the first time the company exceeded $7 million in a quarter. The company achieved positive adjusted EBITDA of $400,000 and generated $700,000 in operating cash flow without a capital raise, demonstrating a successful shift to profitable growth driven by both pathology and record product sales. Management expressed optimism for continued revenue growth and commercial pipeline conversion in the second half of 2026.

Precipio, Inc. announced strong financial results for Q2-2026, with record quarterly revenue exceeding $7 million and a return to positive Adjusted EBITDA of $0.4 million. The specialty cancer diagnostics company also strengthened its cash position, reaching over $3 million, demonstrating healthy operational recovery and continued momentum without external financing. Management anticipates further growth and will discuss these results in a shareholder call.

Precipio Inc (PRPO) reported increased Q2 2026 revenue and adjusted EBITDA, signaling operational improvements, yet its stock appears significantly overvalued by the GF Value™ metric. The company's GF Score™ of 51/100 reflects strong momentum but weaknesses in growth, profitability, and valuation, with insider selling and a guru investor trimming positions suggesting caution. Investors are advised to carefully consider these factors due to the stock's speculative nature and ongoing unprofitability.